News releases - Merck.com
WEBSep 26, 2024 · FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With …
Merck & Co., Inc. (MRK) Latest Stock News & Headlines
WEBGet the latest Merck & Co., Inc. (MRK) stock news and headlines to help you in your trading and investing decisions.
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
WEBMar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. WINREVAIR logo (Graphic: Merck & Co., Inc.)
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating …
WEBFeb 21, 2023 · MOVe-AHEAD (MK-4482-013) (NCT04939428) was a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered LAGEVRIO (molnupiravir) compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households.
News & Stories | Merck
WEBCheck out the latest Merck news and stories! Learn more about the leading science and technology company here.
Merck’s $11.5 Billion Bet on Its Next Big Drug Finally Arrives
WEBMar 26, 2024 · Merck MRK 0.53% is making a big bet that its new drug, approved Tuesday in the U.S. for a potentially fatal lung disease, will take the company a long way toward heading off a massive revenue ...
Merck raises 2024 profit forecast on surging sales of cancer drug ...
WEBApr 25, 2024 · Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine.
FDA approves Merck's drug for rare, deadly lung condition
WEBMar 26, 2024 · The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.
Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO
WEBJan 4, 2024 · Merck & Co is seeking GLP-1 treatments with benefits beyond weight loss, CEO Robert Davis said on Thursday at a conference.
Merck’s fourth-quarter results top estimates, fueled by key cancer ...
WEBFeb 1, 2024 · Merck on Thursday reported fourth-quarter earnings and sales that beat analyst expectations, powered by strong growth in cancer and vaccine products.